This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AERI Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aerie Pharmaceuticals Stock (NASDAQ:AERI) 30 days 90 days 365 days Advanced Chart Get Aerie Pharmaceuticals alerts:Sign Up Key Stats Today's Range$15.25▼$15.2550-Day Range$15.18▼$15.2552-Week Range$4.81▼$15.37Volume600 shsAverage Volume974,748 shsMarket Capitalization$753.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.Read More… Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AERI Stock News HeadlinesROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsightMarch 25, 2025 | finance.yahoo.comUS to donate 1 million mpox vaccine doses to halt outbreak in AfricaSeptember 26, 2024 | reuters.comWhile others chase AI stocks, smart traders do thisSince the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...May 29, 2025 | WealthPress (Ad)Global $20B+ Macular Degeneration Treatment Market Outlook, 2024-2029: AI Integration Paves the Way for Personalized CareMay 10, 2024 | finance.yahoo.com20 Countries With Worst Vision ProblemsFebruary 29, 2024 | uk.finance.yahoo.comParatus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive OfficerFebruary 21, 2024 | finance.yahoo.comJustin Timberlake is ready to Rock Your Body for one night only in Memphis, and for freeJanuary 12, 2024 | msn.comAlcon’s dry eye drug achieves primary endpoints in Phase III trialsJanuary 10, 2024 | msn.comSee More Headlines AERI Stock Analysis - Frequently Asked Questions How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) posted its earnings results on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.10. The company earned $29.31 million during the quarter, compared to analysts' expectations of $29.13 million. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Bristol-Myers Squibb (BMY), Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE) and Melinta Therapeutics (MLNT). Company Calendar Last Earnings11/04/2021Today5/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AERI CIK1337553 Webwww.aeriepharma.com Phone(919) 237-5300Fax949-526-8787Employees376Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.81 million Net Margins-17.09% Pretax Margin-16.47% Return on EquityN/A Return on Assets-2.00% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio1.92 Sales & Book Value Annual Sales$194.13 million Price / Sales3.88 Cash FlowN/A Price / Cash FlowN/A Book Value($3.32) per share Price / Book-4.59Miscellaneous Outstanding Shares49,417,000Free Float47,223,000Market Cap$753.61 million OptionableOptionable Beta-0.06 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AERI) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerie Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerie Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.